MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
Status:
RECRUITING
Trial end date:
2028-09-30
Target enrollment:
Participant gender:
Summary
This phase I trial tests the safety, side effects, best dose of MUC1-activated T cells in treating patients with ovarian cancer that has come back after a period of improvement (relapsed) or that remains despite treatment (resistant). T cells are infection fighting blood cells that can kill tumor cells. The T cells given in this study will come from the patient and are made in a laboratory to recognize MUC1, a protein on the surface of tumor cells that plays a key role in tumor cell growth. These MUC1-activated T cells may help the body's immune system identify and kill MUC1 expressing ovarian tumor cells.
Phase:
PHASE1
Details
Lead Sponsor:
Mayo Clinic
Treatments:
Bendamustine Hydrochloride Cyclophosphamide Leukapheresis Magnetic Resonance Spectroscopy Specimen Handling